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Abstract
Introduction: Stroke is the second leading cause of death in the world. However,
there is still no approved neuroprotective drug for acute ischaemic stroke. To
clarify the neuroprotective efficacy and safety of dextromethorphan in stroke,
the following study was carried out.
Material and methods: Forty patients with acute stroke causing moderate deficit
were randomized to be treated with either dextromethorphan 300 mg per day
or placebo for 5 days. Plasma level of dextromethorphan and its active metabolite
was not evaluated in this study. The NIHSS score was calculated on day 5 and
the Barthel activities of daily living index and Rankin score were checked after
3 months by a blinded investigator. Collected data were analysed using the 
t-test and χ2 test.
Results: In the dextromethorphan-treated group, the mean NIHSS score was
16.8 ±3.9 at baseline, and was 14.2 ±4.8 for the placebo-treated group (p = 0.069).
At day 5, there was also no significant difference regarding NIHSS score 
(p = 0.167). At the 3-month follow-up, there was no significant difference
regarding Barthel scale and Rankin score between the dextromethorphan and
placebo groups. 
Conclusions: The results of our study suggest that although low-dose and short-
term oral administration of dextromethorphan seems to be not neuroprotective,
it does not worsen either patients’ condition or NIHSS score. Moreover, patients
treated with dextromethorphan showed a significant reduction in seizures
(complication after stroke), but had increased chance of MI and renal failure by
almost 5% when compared to the placebo-treated groups. More prolonged
studies with a higher number of cases are recommended.
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Introduction
Stroke is the second leading cause of death in the world [1]. Stroke is
the most common cause of serious, long-term disability in adults. The total
cost of stroke in the USA is estimated to be more than US $56 billion in
2005 [2]. In addition, stroke patients have a high risk of myocardial
infarction or vascular death [3]. During stroke, brain tissue does not obtain
enough nutrients and oxygen and dies within a few hours [1]. Various
therapies such as surgery, medications and post-stroke rehabilitation are
not completely successful in controlling its consequences. Despite
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experimental models, none of them has been
approved to date by the U.S. Food and Drug
Administration for acute ischaemic stroke [1].
Dextromethorphan (an NMDA receptor anta  -
gonist) is a highly effective and widely used non-
opioid antitussive drug [4]. It has been observed to
provide neuroprotection in a variety of in vitro and
in vivo experimental models of central nervous
system (CNS) injury [5-7]. Adverse reactions with this
drug are infrequent and usually not severe [5, 6].
Neuroprotective effects of dextromethorphan in
animal models have been suggested in many
previous studies [5, 8-11]. However, there is a lack
of clinical data regarding use of this medication as
a neuroprotective medication in humans. To better
clarify the efficacy and safety of dextromethorphan
in patients with ischaemic stroke, the following
study was carried out.
Material and methods
This was a randomized placebo-controlled clinical
trial that was performed in Al-Zahra Hospital,
Isfahan, Iran. Ethical committee clearance was
achieved before start of the study. Informed consent
was also obtained from all of the participants. Forty
patients who were in the acute phase of stroke
(deficit having lasted more than 6 h and less than
24 h) and their stroke deficit was of moderate
degree (NIHSS less than 17 and more than 7) were
included in this study. Computed tomography (CT)
scan and relevant laboratory tests were performed
to exclude patients with intra  cerebral, subdural,
epidural or subarachnoid haemorrhage. Patients with
cerebral degenerative, demyelinating diseases, brain
tumour, previous stroke, metabolic disorders and
muscular or neuromuscular junction diseases were
also excluded. 
To have a homogeneous study group, only
patients with middle cerebral artery territory
infarction (based on Duplex sonography of the
cervical artery and transcranial Doppler and CT scan
on admission and the 2nd day after stroke and
correlation with neurological examination) were
included.
All of the patients were examined and scored
using the National Institutes of Health Stroke Scale
(NIHSS) by a blinded investigator on the admission
day and the 5th day. The patients were randomized
into 2 groups each including 20 patients. Group A
was treated with a 60 mg loading dose of oral
dextromethorphan and daily oral 300 mg of
dextromethorphan divided into 5 doses for 5 days.
Group B were treated with a placebo that was
made of the basic materials of the tablet. Both the
drug and placebo were provided by Poor Sina
Company.
All of the patients were also treated with
acetylsalicylic acid (enteric coated) 80 mg, daily.
Both the active and placebo groups received the
acetylsalicylic acid. It has already been shown that
salicylic acid does not affect the plasma level of
dextromethorphan and its metabolite [12]. No other
medication was prescribed for the patients. 
The Barthel activities of daily living index and
Rankin score were checked after 3 months by
a blinded investigator. The study end point was the
completion of the 90-day follow-up period.
Collected data were analysed using SPSS version
15.00 software and statistical tests including t-test
and χ2 test.
Results
Forty patients (20 treated with dextro  -
methorphan and 20 receiving placebo) entered the
study. The mean age in the dextromethorphan
group was 68.65 years and in the placebo group
was 69.25 years and there was no significant
difference regarding age between the 2 groups 
(p = 0.86). Out of 20 patients in the dextro  -
methorphan group, 12 patients (60%) were male
and 8 patients (40%) were female. Out of 20 pa  -
tients in the placebo group, 7 patients (35%) were
male and 13 patients (65%) were female (Table I).
There was no significant difference regarding risk
factors between the dextromethorphan and placebo
groups (Table II). Complications of stroke were seen
in both groups (after 5 days of administration of
drug or placebo) (Figure 1). However, no acute or
chronic side effects attributable to dextro  methor  -
phan were observed. 
In the dextromethorphan-treated group, the
mean NIHSS score was 16.8 ±3.9 at baseline, and
was 14.2 ±4.8 for the placebo-treated group. There
was no significant difference regarding NIHSS score
at baseline (p = 0.069) (Figure 3). At day 5, there
was also no significant difference regarding NIHSS
score (p = 0.167) (Figure 4, Table III). At the 3-month
follow-up, there was no significant difference
regarding Barthel scale between the dextromethor  -
phan and placebo groups (p = 0.268) (Table IV).
In addition, at the 3-month follow-up, there was
no significant difference regarding Rankin scale
between the dextromethorphan and placebo
groups (p = 0.268) (Table V).
Treatment groupD extromethorphan Placebo
Mean of age [years] 68.65  69.25
M/F (out of 20 patients) 12/8 7/13
Lag time to start  11.9 10.4
treatment [h]
Table I. Demographic characteristics of the patients
in the dextromethorphan and placebo groups 
(p > 0.05)
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Treatment groupD extromethorphan Placebo Value of p
Hypertension history (+/–)  11/9 (55%/45%) 16/4 (80%/20%) 0.088
Hyperlipidemia (+/–) 2/18 (10%/90%) 6/14 (30%/70%) 0.118
Ischemic Heart Disease (+/–) 6/14 (30%/70%) 5/15 (25%/75%) 0.5
Smoking (+/–) 7/13 (35%/65%) 4/16 (20%/80%) 0.24
Opium Addiction(+/–) 2/18 (10%/90%) 0/20 (0%/100%) 0.244
Table II. Comparison between risk factors in the dextromethorphan and placebo groups
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Figure 1. Complications of stroke in the dextro  -
methorphan and placebo groups (after 5 days’
administration of drug or placebo)
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Figure 2. Age distribution of patients in the 2 groups
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Figure 3. Comparison of NIHSS score at day 1 in the
dextromethorphan and placebo groups
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Figure 4. Comparison of NIHSS score at day 5 in the
dextromethorphan and placebo groups
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NIHSS N Mean Standard deviation Standard error, mean
Day 1 Dextromethorphan 20 16.85 3.93 0.88
Placebo 20 14.25 4.81 1.07
Day 5 Dextromethorphan 20 17.25 7.62 1.70
Placebo 20 13.5 9.12 2.03
Table III. Comparisson of the NIHSS between the dextrometorhphan and placebo groups at day 1 and day 5468 Arch Med Sci 3, June / 2011
Discussion
Many preclinical studies have shown the
neuroprotective properties of dextromethorphan
in various CNS injury models including focal and
global ischaemia, seizure, and traumatic brain injury.
Many of these protective actions seem functionally
related to its inhibitory effects on glutamate-
induced neurotoxicity via NMDA receptor anta  -
gonist, sigma-1 receptor agonist, and voltage-gated
calcium channel antagonist actions.  The capability
of dextromethorphan to protect dopamine neurons
in Parkinson models may be due to inhibition of
neurodegenerative inflammatory responses [13].
Albers et al. treated 10 patients with a history of
recent stroke with oral dextromethorphan (60 mg
q.i.d.) for 3 weeks in a placebo-controlled, double-
blind, and crossover tolerance study. They
documented no clinical evidence of toxicity
attributed to dextromethorphan in this preliminary
study [14]. Also in another study by Albers et al.
similar results were obtained; however, side effects
including lightheadedness, drowsiness, nausea,
decreased coordination, and unsteady gait were
reported by several patients [15-17]. In the current
study, we used shorter duration of treatment but
with a higher number of patients. We also observed
no evidence of toxicity attributable to dextro  -
methor  phan.
Steinberg et al. found that in rabbits with focal
ischaemia the area of neocortical ischaemic
neuronal damage was significantly reduced in the
group treated with dextromethorphan compared
with controls [18]. In addition other studies have
shown a neuroprotective effect of dextromethor  -
phan in animal models [8-11].
We chose dextromethorphan as a neuropro  -
tective agent because of its assumed neuro  -
protective effect (as shown by animal studies), its
safety and its effect on control of seizures and
headaches [4-7, 13, 14, 19, 20].
Because the majority of stroke patients arrive at
the hospital several hours after appearance of
symptoms, the therapeutic window of 24 h was our
proposed design. However, the usually accepted
therapeutic window for neuroprotective medi  -
cations is up to 6 h. Therefore, more studies
proposing this fact are recommended. Nevertheless,
animal model studies have shown that evaluation
of inclusive changes to infarction is not limited to
the first 24 h [7, 18]. In the current study, plasma
levels of dextromethorphan and its active
metabolite were not evaluated. 
The results of our study suggest that although
low-dose and short-term oral administration of
dextromethorphan seems not to be neuropro  -
tective, it does not worsen either patients’ condition
or NIHSS score. In addition, patients treated with
dextromethorphan showed significant reduction in
seizures (complication after stroke), but increased
chance of MI and renal failure by almost 5% when
compared to the placebo-treated group.
The current study was the first clinical trial to
evaluate the neuroprotective effect of dextro  -
methorphan in stroke patients. Regarding the lack
of clinical data about using dextromethorphan as
a neuroprotective agent and the risk of possible
side effects, we designed this study with a limited
number of patients and short duration of the
treatment. The results of the current study showed
no significant improvement of the neurological
deficit in the dextromethorphan-treated group as
compared with the control group. Rankin and
disability score and Barthel activities of daily living
index also did not show any significant difference
between groups. However, to better clarify the
neuroprotective effect of this agent, more extensive
studies with longer duration of the treatment and
follow-up are recommended.
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